HUE028361T2 - Antigen binding proteins capable of binding thymic stromal lymphopoietin - Google Patents

Antigen binding proteins capable of binding thymic stromal lymphopoietin Download PDF

Info

Publication number
HUE028361T2
HUE028361T2 HUE08830362A HUE08830362A HUE028361T2 HU E028361 T2 HUE028361 T2 HU E028361T2 HU E08830362 A HUE08830362 A HU E08830362A HU E08830362 A HUE08830362 A HU E08830362A HU E028361 T2 HUE028361 T2 HU E028361T2
Authority
HU
Hungary
Prior art keywords
antibody
tslp
sequence
antibodies
human
Prior art date
Application number
HUE08830362A
Other languages
English (en)
Hungarian (hu)
Inventor
Michael R Comeau
James F Smothers
Bo-Rin P Yoon
Christopher Mehlin
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40242598&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE028361(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of HUE028361T2 publication Critical patent/HUE028361T2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE08830362A 2007-09-10 2008-09-09 Antigen binding proteins capable of binding thymic stromal lymphopoietin HUE028361T2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97117807P 2007-09-10 2007-09-10
US9167608P 2008-08-25 2008-08-25

Publications (1)

Publication Number Publication Date
HUE028361T2 true HUE028361T2 (en) 2016-12-28

Family

ID=40242598

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE08830362A HUE028361T2 (en) 2007-09-10 2008-09-09 Antigen binding proteins capable of binding thymic stromal lymphopoietin
HUS2200051C HUS2200051I1 (hu) 2007-09-10 2022-12-12 Csecsemõmirigy sztrómális limfopoietin megkötésére képes antigén-kötõ fehérjék

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUS2200051C HUS2200051I1 (hu) 2007-09-10 2022-12-12 Csecsemõmirigy sztrómális limfopoietin megkötésére képes antigén-kötõ fehérjék

Country Status (36)

Country Link
US (6) US7982016B2 (enExample)
EP (3) EP3524622A1 (enExample)
JP (8) JP5956716B2 (enExample)
KR (2) KR20140141666A (enExample)
CN (2) CN104231081B (enExample)
AR (1) AR068508A1 (enExample)
AU (1) AU2008300028B2 (enExample)
CA (1) CA2698382C (enExample)
CL (2) CL2008002668A1 (enExample)
CR (2) CR11319A (enExample)
CY (2) CY1117702T1 (enExample)
DK (1) DK2205635T3 (enExample)
EA (2) EA022796B1 (enExample)
ES (1) ES2581229T3 (enExample)
FR (1) FR22C1059I2 (enExample)
HR (1) HRP20160638T1 (enExample)
HU (2) HUE028361T2 (enExample)
IL (3) IL204069A (enExample)
JO (1) JO3351B1 (enExample)
LT (2) LT2205635T (enExample)
LU (1) LUC00289I2 (enExample)
MX (1) MX2010002590A (enExample)
MY (1) MY150242A (enExample)
NL (1) NL301207I2 (enExample)
NO (1) NO2022055I1 (enExample)
NZ (1) NZ583933A (enExample)
PE (2) PE20110668A1 (enExample)
PH (1) PH12017501025B1 (enExample)
PL (1) PL2205635T3 (enExample)
PT (1) PT2205635T (enExample)
RS (1) RS54950B1 (enExample)
SG (2) SG10201506251YA (enExample)
SI (1) SI2205635T1 (enExample)
TW (2) TW201412774A (enExample)
WO (1) WO2009035577A1 (enExample)
ZA (1) ZA201001895B (enExample)

Families Citing this family (164)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0603683D0 (en) * 2006-02-23 2006-04-05 Novartis Ag Organic compounds
KR20090088950A (ko) 2006-12-14 2009-08-20 쉐링 코포레이션 가공된 항-ｔｓｌｐ 항체
CA2711826C (en) 2008-01-25 2018-02-27 Amgen Inc. Ferroportin antibodies and methods of use
WO2011056772A1 (en) 2009-11-04 2011-05-12 Schering Corporation Engineered anti-tslp antibody
CA2885176C (en) * 2010-09-22 2018-10-23 Amgen Inc. Carrier immunoglobulins and uses thereof
US9732151B2 (en) * 2011-11-03 2017-08-15 Merck Sharp & Dohme Corp. Biomarkers for TSLP treatment
PT2841456T (pt) * 2012-04-27 2018-10-19 Novo Nordisk As Proteinas de ligação ao antigénio do ligando de cd30 humano
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
CN104371019B (zh) * 2013-08-13 2019-09-10 鸿运华宁（杭州）生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
WO2015035215A1 (en) 2013-09-05 2015-03-12 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
WO2015118124A1 (en) * 2014-02-06 2015-08-13 Vib Vzw Thymic stromal lymphopoietin receptor antagonist
SG10201811702TA (en) 2014-05-07 2019-01-30 Amgen Inc Autoinjector with shock reducing elements
EP3143404B1 (en) 2014-05-16 2018-08-29 Amgen Inc. Assay for detecting th1 and th2 cell populations
MX387194B (es) 2014-06-03 2025-03-18 Amgen Inc Sistemas y metodos para procesar de manera remota datos recolectados por un dispositivo de suministro de farmaco.
EP3943135B1 (en) 2014-10-14 2025-09-24 Amgen Inc. Drug injection device with visual and audible indicators
MA54716A (fr) 2014-10-23 2021-11-17 Amgen Inc Réduction de la viscosité de formulations pharmaceutiques
EP3689394A1 (en) 2014-12-19 2020-08-05 Amgen Inc. Drug delivery device with live button or user interface field
ES2748750T3 (es) 2015-02-17 2020-03-17 Amgen Inc Dispositivo de administración de fármacos con sujeción asistida por vacío y/o realimentación
US11806509B2 (en) 2015-02-27 2023-11-07 Amgen Inc. Drug delivery device having a needle guard mechanism with a turnable threshold of resistance to needle guard movement
AU2016231122A1 (en) * 2015-03-11 2017-09-07 Glaxosmithkline Intellectual Property Development Limited TSLP binding proteins
CN111234027A (zh) * 2015-05-21 2020-06-05 哈普恩治疗公司 三特异性结合蛋白质及使用方法
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
MY186352A (en) * 2015-09-09 2021-07-15 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
RS61763B1 (sr) 2015-09-09 2021-05-31 Novartis Ag Antitela koja vezuju timusni stromalni limfopoetin (tslp) i metode za korišćenje antitela
US11351308B2 (en) 2015-12-09 2022-06-07 Amgen Inc. Auto-injector with signaling cap
US11154661B2 (en) 2016-01-06 2021-10-26 Amgen Inc. Auto-injector with signaling electronics
AR107505A1 (es) 2016-01-22 2018-05-09 Merck Sharp & Dohme Anticuerpos anti-factor de la coagulación xi
GB201615588D0 (en) * 2016-09-14 2016-10-26 Glaxosmithkline Ip Dev Ltd TSLP Binding Proteins
EP3429663B1 (en) 2016-03-15 2020-07-15 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
KR20180132766A (ko) 2016-04-05 2018-12-12 브이아이비 브이지더블유 신규한 ｔｓｌｐ 저해인자
US11541168B2 (en) 2016-04-29 2023-01-03 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
JP7309363B2 (ja) 2016-05-13 2023-07-18 アムジエン・インコーポレーテツド バイアル・スリーブ組立体
US11238150B2 (en) 2016-05-16 2022-02-01 Amgen Inc. Data encryption in medical devices with limited computational capability
WO2017209899A1 (en) 2016-06-03 2017-12-07 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
KR102218714B1 (ko) 2016-06-14 2021-02-24 머크 샤프 앤드 돔 코포레이션 항응고 인자 xi 항체
EP3478342B1 (en) 2016-07-01 2025-03-12 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
US10919966B2 (en) * 2016-08-05 2021-02-16 Y-Biologics Inc. Antibody to programmed death-ligand 1 (PD-L1) and use thereof
WO2018034784A1 (en) 2016-08-17 2018-02-22 Amgen Inc. Drug delivery device with placement detection
US20200261643A1 (en) 2016-10-25 2020-08-20 Amgen Inc. On-body injector
TWI857389B (zh) 2016-12-01 2024-10-01 美商再生元醫藥公司 治療發炎症狀的方法
MX2019008432A (es) 2017-01-17 2019-11-18 Amgen Inc Dispositivos de inyeccion y metodos relacionados de uso y ensamblaje.
PT3383916T (pt) * 2017-01-24 2022-03-30 I Mab Biopharma Us Ltd Anticorpos anti-cd73 e seus usos
US11752258B2 (en) 2017-02-17 2023-09-12 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
MX2019009755A (es) 2017-02-17 2019-10-07 Amgen Inc Mecanismo de insercion para dispositivo de suministro de farmacos.
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
WO2018165143A1 (en) 2017-03-06 2018-09-13 Amgen Inc. Drug delivery device with activation prevention feature
WO2018164829A1 (en) 2017-03-07 2018-09-13 Amgen Inc. Needle insertion by overpressure
IL268386B2 (en) 2017-03-09 2023-11-01 Amgen Inc Insertion mechanism for a drug delivery device
CN110418846A (zh) 2017-03-14 2019-11-05 美国安进公司 细胞培养物中产生的抗体的总去岩藻糖基化糖型的控制
PL3600491T3 (pl) 2017-03-28 2024-03-04 Amgen Inc. Układ i sposób montażu trzonu tłoka i strzykawki
JOP20190243A1 (ar) 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp
AU2018258676B2 (en) 2017-04-28 2024-09-19 Amgen Inc. N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides
EP3634546A1 (en) 2017-06-08 2020-04-15 Amgen Inc. Torque driven drug delivery device
WO2018226515A1 (en) 2017-06-08 2018-12-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
WO2018236619A1 (en) 2017-06-22 2018-12-27 Amgen Inc. Device activation impact/shock reduction
JP7475860B2 (ja) 2017-06-23 2024-04-30 アムジエン・インコーポレーテツド スイッチアセンブリにより起動されるキャップを含む電子薬物送達デバイス
CN109206514B (zh) * 2017-07-03 2019-10-08 拜西欧斯（北京）生物技术有限公司 Tslp单克隆抗体及其制备方法和应用
EP3651832B1 (en) 2017-07-14 2023-12-13 Amgen Inc. Needle insertion-retraction system having dual torsion spring system
US11672733B2 (en) 2017-07-21 2023-06-13 Amgen Inc. Gas permeable sealing member for drug container and methods of assembly
JP7242562B2 (ja) 2017-07-25 2023-03-20 アムジエン・インコーポレーテツド 容器アクセスシステムを有する薬物送達デバイス及び関連する組立方法
JP2020528296A (ja) 2017-07-25 2020-09-24 アムジエン・インコーポレーテツド ギヤモジュールを有する薬物送達デバイス及び関連する組立方法
EA202090380A1 (ru) 2017-08-01 2020-05-21 Эмджен Инк. Системы и способы для выполнения анализа гликанов в образце в режиме реального времени
EA202090399A1 (ru) 2017-08-01 2020-05-20 Эмджен Инк. Системы и способы для подготовки в режиме реального времени образца полипептида для анализа с помощью масс-спектрометрии
US12318593B2 (en) 2017-08-09 2025-06-03 Amgen Inc. Hydraulic-pneumatic pressurized chamber drug delivery system
AU2018318435A1 (en) 2017-08-16 2020-04-02 Medimmune, Llc Compositions and methods for treatment of atopic dermatitis and treatment selection
EP3668567A1 (en) 2017-08-18 2020-06-24 Amgen Inc. Wearable injector with sterile adhesive patch
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
US11759565B2 (en) 2017-10-04 2023-09-19 Amgen Inc. Flow adapter for drug delivery device
EP3691716B1 (en) 2017-10-06 2023-11-29 Amgen Inc. Drug delivery device with interlock assembly and related method of assembly
IL273323B2 (en) 2017-10-09 2024-10-01 Amgen Inc Drug delivery device with drive assembly and related assembly method
UA129446C2 (uk) 2017-10-13 2025-04-30 Гарпун Терап'Ютікс, Інк. Триспецифічні білки і способи їх застосування
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
US11826480B2 (en) 2017-11-03 2023-11-28 Amgen Inc. Systems and approaches for sterilizing a drug delivery device
MA50553A (fr) 2017-11-06 2020-09-16 Amgen Inc Dispositif d'administration de médicament avec détection de positionnement et de débit
MA50569A (fr) 2017-11-06 2020-09-16 Amgen Inc Ensembles de remplissage-finition et procédés associés
SG11202002966QA (en) 2017-11-10 2020-05-28 Amgen Inc Plungers for drug delivery devices
AU2018368340B2 (en) 2017-11-16 2024-03-07 Amgen Inc. Door latch mechanism for drug delivery device
AU2019234846A1 (en) 2018-03-13 2020-09-24 Amgen Inc. Sequential digestion of polypeptides for mass spectrometric analysis
EP3765856B1 (en) 2018-03-13 2023-09-27 Amgen Inc. Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis
SG11202009216YA (en) 2018-03-26 2020-10-29 Amgen Inc Total afucosylated glycoforms of antibodies produced in cell culture
WO2019222283A1 (en) 2018-05-14 2019-11-21 Harpoon Therapeutics, Inc. Binding moiety for conditional activation of immunoglobulin molecules
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
WO2020023220A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
EP3826701A1 (en) 2018-07-24 2021-06-02 Amgen Inc. Delivery devices for administering drugs
MX2021000749A (es) 2018-07-24 2021-03-29 Amgen Inc Dispositivos de suministro para administrar farmacos.
WO2020028009A1 (en) 2018-07-31 2020-02-06 Amgen Inc. Fluid path assembly for a drug delivery device
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
JP2022500095A (ja) 2018-09-24 2022-01-04 アムジエン・インコーポレーテツド インターベンション投薬システム及び方法
EP3856771A4 (en) 2018-09-25 2022-06-29 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
IL281469B2 (en) 2018-09-28 2024-08-01 Amgen Inc Muscle wire escapement activation assembly for a drug delivery device
EP3860685A1 (en) 2018-10-02 2021-08-11 Amgen Inc. Injection systems for drug delivery with internal force transmission
US12151089B2 (en) 2018-10-05 2024-11-26 Amgen Inc. Drug delivery device having dose indicator
MA53912A (fr) 2018-10-15 2022-01-19 Amgen Inc Dispositif d'administration de médicament comprenant un mécanisme d'amortissement
SG11202101824VA (en) 2018-10-15 2021-03-30 Amgen Inc Platform assembly process for drug delivery device
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
EP3873566B1 (en) 2018-11-01 2024-11-27 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
AU2019370159B2 (en) 2018-11-01 2025-05-29 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
AU2019396614B2 (en) 2018-12-14 2025-07-10 Amgen Inc. System suitability method for use with protein concentration determination by slope
US11452738B2 (en) 2019-01-04 2022-09-27 Empirico Inc. Treatment of thymic stromal lymphopoietin (TSLP) related diseases by inhibition of long-form TSLP transcripts
ES2987091T3 (es) 2019-02-14 2024-11-13 Amgen Inc Sistemas y métodos para preparar una muestra y realizar un ensayo en tiempo real de la muestra
AU2020226619A1 (en) 2019-02-20 2021-08-05 Amgen Inc. Methods of determining protein stability
US20230035363A1 (en) 2019-03-04 2023-02-02 Amgen Inc. In vivo reversibility of high molecular weight species
US12078701B2 (en) 2019-03-27 2024-09-03 Amgen Inc. Methods of fingerprinting therapeutic proteins via a two-dimensional (2D) nuclear magnetic resonance technique at natural abundance for formulated biopharmaceutical products
US20220160972A1 (en) 2019-04-24 2022-05-26 Amgen Inc. Syringe sterilization verification assemblies and methods
WO2020244544A1 (zh) 2019-06-04 2020-12-10 江苏恒瑞医药股份有限公司 能结合胸腺基质淋巴细胞生成素的抗体及其应用
ES2997211T3 (en) 2019-06-05 2025-02-14 Amgen Inc Methods of identifying attributes of therapeutic proteins
US12435131B2 (en) 2019-07-11 2025-10-07 Tavotek Biotherapeutics (Hong Kong) Limited Agents that interfere with thymic stromal lymphopoietin (TSLP)-receptor signaling
JP7608439B2 (ja) 2019-08-23 2025-01-06 アムジエン・インコーポレーテツド 構成可能な針シールド係合構成要素を備えた薬物送達デバイス及び関連方法
KR20220069982A (ko) 2019-09-26 2022-05-27 암젠 인크 항체 조성물의 생산 방법
UA129038C2 (uk) 2019-10-28 2024-12-25 Медіммуне Лімітед Сухий порошкоподібний склад антитіла, що зв'язує тимічний стромальний лімфопоетин (tslp)
CN112876564B (zh) * 2019-11-29 2022-07-15 康诺亚生物医药科技（成都）有限公司 一种tslp相关病症治疗剂的开发和应用
KR20220113673A (ko) * 2019-12-13 2022-08-16 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 항-tslp 항체 및 그 용도
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
CN111171150B (zh) * 2020-02-05 2020-12-08 北京智仁美博生物科技有限公司 抗人tslp抗体及其用途
IL295042A (en) 2020-02-13 2022-09-01 Amgen Inc Formulations of human anti-tslp antibodies and methods of treating inflammatory disease
US20230073888A1 (en) 2020-02-13 2023-03-09 Amgen Inc. Treatment of atopic dermatitis with anti-tslp antibody
AR121368A1 (es) 2020-02-18 2022-06-01 Amgen Inc Formulaciones de anticuerpos anti-tslp humanos y métodos de uso de los mismos
CN111662379B (zh) * 2020-05-09 2021-03-02 江苏省疾病预防控制中心(江苏省公共卫生研究院) 抗新型冠状病毒的抗体、制备方法和应用
WO2021236997A2 (en) * 2020-05-20 2021-11-25 The Trustees Of Columbia University In The City Of New York Potent neutralizing antibodies against sars-cov-2, generation and uses thereof
WO2021247892A1 (en) 2020-06-04 2021-12-09 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
WO2022061092A1 (en) 2020-09-18 2022-03-24 Amgen Inc. Methods of processing a sample for peptide mapping analysis
AU2021360897A1 (en) 2020-10-15 2023-05-25 Amgen Inc. Relative unpaired glycans in antibody production methods
WO2022098595A1 (en) 2020-11-05 2022-05-12 Amgen Inc. Materials and methods for protein processing
CN114437212B (zh) * 2020-11-06 2023-03-14 上海麦济生物技术有限公司 抗人胸腺基质淋巴细胞生成素抗体及其制备方法和应用
WO2022117079A1 (zh) * 2020-12-03 2022-06-09 江苏恒瑞医药股份有限公司 结合胸腺基质淋巴细胞生成素的抗体及其应用
CN113501878B (zh) 2021-02-03 2022-12-02 北京智仁美博生物科技有限公司 针对人tslp的多种抗体及其用途
WO2022166739A1 (en) * 2021-02-04 2022-08-11 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing thymic stromal lymphopoietin and uses thereof
MX2023012363A (es) 2021-04-23 2023-11-01 Amgen Inc Composiciones de anticuerpos anti-tslp y usos de las mismas.
KR20230175245A (ko) 2021-04-23 2023-12-29 암젠 인크 변형된 항-tslp 항체
US20240208680A1 (en) 2021-05-21 2024-06-27 Amgen Inc. Method of optimizing a filling recipe for a drug container
BR112023025039A2 (pt) * 2021-05-30 2024-02-20 Biolojic Design Ltd Anticorpos de ligação dupla manipulados e usos dos mesmos
CN113069543B (zh) * 2021-06-07 2021-08-06 迈威(上海)生物科技股份有限公司 包含抗胸腺基质淋巴细胞生成素的单克隆抗体的液体组合物
TW202317614A (zh) 2021-06-07 2023-05-01 美商安進公司 使用岩藻糖苷酶控制糖基化蛋白的去岩藻糖基化水平
CN113683694B (zh) 2021-09-03 2022-05-13 江苏荃信生物医药股份有限公司 一种抗人tslp单克隆抗体及其应用
JP2024537100A (ja) 2021-10-05 2024-10-10 アムジエン・インコーポレーテツド Ｆｃガンマ受容体ＩＩ結合、及びグリカン含量
WO2023070948A1 (zh) * 2021-11-01 2023-05-04 江苏荃信生物医药股份有限公司 包含抗人胸腺基质淋巴细胞生成素(tslp)单克隆抗体的浓缩溶液的制备方法及液体制剂
EP4430174A1 (en) 2021-11-09 2024-09-18 Amgen Inc. Production of therapeutic proteins
CN117209604B (zh) * 2021-12-02 2024-03-22 北京东方百泰生物科技股份有限公司 一种抗tslp的单克隆抗体、其抗原结合片段及其应用
CN114369654B (zh) * 2021-12-21 2023-11-07 广州市妇女儿童医疗中心 川崎病的生物标志物及其应用
EP4453030A1 (en) * 2021-12-24 2024-10-30 Inmagene Pte. Ltd. Novel anti-tslp antibodies
CA3254037A1 (en) * 2022-03-03 2023-09-07 Pfizer MULTISPECIFIC ANTIBODIES AND THEIR USES
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
US12110324B2 (en) * 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
CN118580343B (zh) * 2022-10-21 2025-08-19 珠海泰诺麦博制药股份有限公司 抗人巨细胞病毒抗体及其用途
UY40500A (es) 2022-10-26 2024-04-30 Amgen Inc Composiciones de anticuerpos anti-tslp y usos de las mismas
TW202448501A (zh) 2023-02-02 2024-12-16 美商麥迪紐有限責任公司 用抗ｔｓｌｐ抗體治療慢性鼻竇炎
WO2024174895A1 (zh) * 2023-02-23 2024-08-29 四川科伦博泰生物医药股份有限公司 一种靶向tslp的单克隆抗体制剂
WO2024220916A1 (en) 2023-04-20 2024-10-24 Amgen Inc. Methods of determining relative unpaired glycan content
AU2024274293A1 (en) 2023-05-18 2025-11-27 Medimmune, Llc Treatment of corticosteroid dependent asthma with anti-tslp antibody
WO2024259275A1 (en) 2023-06-14 2024-12-19 Bristol-Myers Squibb Company Near real time sialic acid quantitation of glycoproteins
WO2024264003A2 (en) * 2023-06-22 2024-12-26 Paragon Therapeutics, Inc. Antibodies that bind interleukin 13 and tslp or tslpr and methods of use
WO2024264002A2 (en) * 2023-06-22 2024-12-26 Paragon Therapeutics, Inc. Antibodies that bind tslp and tslpr and methods of use
WO2025038600A1 (en) 2023-08-14 2025-02-20 Amgen Inc. Methods for reducing yellow color
AR133647A1 (es) 2023-08-25 2025-10-22 Proteologix Us Inc Constructos de anticuerpos multiespecíficos anti-il-13 y usos de los mismos
WO2025077831A1 (en) * 2023-10-12 2025-04-17 Innovent Biologics (Suzhou) Co., Ltd. Anti-il-4ra/tslp antibodies and uses thereof
WO2025101602A1 (en) 2023-11-07 2025-05-15 Amgen Inc. Methods of analyzing amino acid content of a therapeutic protein
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2025147632A1 (en) 2024-01-05 2025-07-10 Medimmune, Llc Treatment of chronic obstructive pulmonary disease with anti-tslp antibody
WO2025221247A1 (en) 2024-04-17 2025-10-23 Amgen Inc. Treatment of eosinophilic esophagitis with anti-tslp antibody

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
USRE32011E (en) 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
JPS58117537A (ja) 1982-01-06 1983-07-13 Toray Ind Inc 感光性樹脂組成物
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AU629958B2 (en) 1989-06-15 1992-10-15 Immunex Corporation Interleukin-7 receptors
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
EP0639079B1 (en) 1992-04-30 2000-01-12 Amgen Inc. Methods for treating interleukin-1 and tumor necrosis factor mediated diseases
JP3589665B2 (ja) 1992-10-23 2004-11-17 イミュネックス・コーポレーション 可溶性オリゴマー蛋白質の調製法
EP0737071A1 (en) 1993-06-15 1996-10-16 Il- Yang Pharm. Co., Ltd. Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
GB9702944D0 (en) 1997-02-13 1997-04-02 Univ Manchester Reducing fibrosis
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
EP0985039B1 (en) 1997-06-12 2008-02-20 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6844170B1 (en) * 1998-03-19 2005-01-18 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
EP1093457B8 (en) 1998-03-19 2011-02-02 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
US6982320B2 (en) 1998-03-19 2006-01-03 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
EP2314696A1 (en) 1998-09-21 2011-04-27 Schering Corporation Therapeutic uses of human Interleukin-B50 antagonist.
US20030099947A1 (en) 1998-09-21 2003-05-29 Bazan J. Fernando Mammalian cytokines; related reagents and methods
ES2288036T5 (es) * 1998-11-13 2017-07-06 Immunex Corporation ADN de TSLP humano y polipéptidos
WO2000039149A2 (en) 1998-12-30 2000-07-06 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
AU2001259758A1 (en) 2000-05-12 2001-11-26 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
WO2002000723A2 (en) 2000-06-28 2002-01-03 Whitehead Institute For Biomedical Research Thymic stromal lymphopoietin receptor molecules and uses thereof
PT2077279E (pt) 2000-06-28 2012-09-14 Amgen Inc Moléculas do receptor de linfopoietina estromal tímica e suas utilizações
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
CN1234728C (zh) * 2001-05-16 2006-01-04 上海睿星基因技术有限公司 新的人淋巴因子、其编码序列及用途
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
DK1417231T3 (da) 2001-07-23 2013-07-22 Immunex Corp Modificeret human thymisk stromal lymphopoietin
MXPA04007426A (es) * 2002-02-01 2004-10-11 Schering Corp Usos de citosina de mamifero; reactivos relacionados.
HRP20020453A2 (en) 2002-05-23 2003-12-31 Pliva D D 1,3-diaza-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediate for preparation thereof
PL377091A1 (pl) 2002-09-06 2006-01-23 Amgen, Inc. Ludzkie monoklonalne przeciwciało przeciw-IL-1R1, o właściwościach terapeutycznych
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
JP5436753B2 (ja) 2003-07-18 2014-03-05 メルク・シャープ・アンド・ドーム・コーポレーション 胸腺間質性リンホポエチンを使用する、新生物の処置および診断
RS53476B (sr) 2003-07-18 2014-12-31 Amgen Fremont Inc. Sredstva za specifično vezivanje faktora rasta hepatocita
WO2005063816A2 (en) 2003-12-19 2005-07-14 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
US20050249712A1 (en) * 2004-03-23 2005-11-10 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for use of TSLP and agonists and antagonists thereof
AU2005277236A1 (en) 2004-08-20 2006-03-02 Amgen Inc. Methods and compositions for treating allergic inflammation
MX2007005866A (es) * 2004-11-17 2007-11-12 Amgen Inc Anticuerpos monoclonales totalmente humanos para il-13.
EP1909831A4 (en) 2005-06-14 2013-02-20 Amgen Inc SELF-BUFFING PROTEIN FORMULATIONS
EP2287196A3 (en) 2006-01-13 2011-05-04 Irm Llc Antibodies against thymic stromal lymphopoietin receptor for treating allergic diseases
GB0603683D0 (en) * 2006-02-23 2006-04-05 Novartis Ag Organic compounds
KR20090088950A (ko) 2006-12-14 2009-08-20 쉐링 코포레이션 가공된 항-ｔｓｌｐ 항체
WO2008155365A1 (en) 2007-06-20 2008-12-24 Irm Llc Methods and compositions for treating allergic diseases
US9401875B2 (en) 2012-06-01 2016-07-26 Nippon Telegraph And Telephone Corporation Packet transfer processing method and packet transfer processing device
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
US20090238823A1 (en) 2009-09-24
NL301207I1 (nl) 2022-12-21
KR20140141666A (ko) 2014-12-10
KR101597371B1 (ko) 2016-02-26
DK2205635T3 (en) 2016-07-18
JP2023065375A (ja) 2023-05-12
US20110274687A1 (en) 2011-11-10
JP2021191758A (ja) 2021-12-16
HUS2200051I1 (hu) 2022-12-28
ES2581229T3 (es) 2016-09-02
PE20140232A1 (es) 2014-02-28
CA2698382C (en) 2015-07-14
CL2012003245A1 (es) 2013-03-22
LT2205635T (lt) 2016-09-26
EA022796B1 (ru) 2016-03-31
JP2020058365A (ja) 2020-04-16
CN101809035A (zh) 2010-08-18
EP3524622A1 (en) 2019-08-14
IL265854A (en) 2019-06-30
JP2010538608A (ja) 2010-12-16
AU2008300028A1 (en) 2009-03-19
TWI449709B (zh) 2014-08-21
SI2205635T1 (sl) 2016-09-30
AR068508A1 (es) 2009-11-18
JP2017110011A (ja) 2017-06-22
PL2205635T3 (pl) 2016-12-30
FR22C1059I2 (fr) 2023-12-22
US20120190829A1 (en) 2012-07-26
EA201590631A1 (ru) 2016-03-31
CA2698382A1 (en) 2009-03-19
CL2008002668A1 (es) 2009-08-14
PE20110668A1 (es) 2011-10-01
CY2022036I1 (el) 2023-01-05
JP2024161358A (ja) 2024-11-19
US7982016B2 (en) 2011-07-19
ZA201001895B (en) 2011-02-23
CN104231081B (zh) 2022-01-11
US20200071393A1 (en) 2020-03-05
JP2019038843A (ja) 2019-03-14
JO3351B1 (ar) 2019-03-13
CR11319A (es) 2010-04-21
JP2015091820A (ja) 2015-05-14
PH12017501025A1 (en) 2018-01-29
PH12017501025B1 (en) 2022-10-26
LTC2205635I2 (enExample) 2025-10-27
EP2205635B1 (en) 2016-05-25
US20250154241A1 (en) 2025-05-15
EA201000471A1 (ru) 2010-10-29
IL204069A (en) 2017-03-30
WO2009035577A1 (en) 2009-03-19
RS54950B1 (sr) 2016-11-30
TW200918554A (en) 2009-05-01
NZ583933A (en) 2012-07-27
JP5956716B2 (ja) 2016-07-27
PT2205635T (pt) 2016-07-13
US20160152700A1 (en) 2016-06-02
CR20150095A (es) 2015-04-06
KR20100067660A (ko) 2010-06-21
HK1145843A1 (zh) 2011-05-06
HRP20160638T1 (hr) 2016-07-01
US9284372B2 (en) 2016-03-15
NO2022055I1 (no) 2022-12-09
CY2022036I2 (el) 2023-03-24
CN104231081A (zh) 2014-12-24
CN101809035B (zh) 2014-07-09
AU2008300028B2 (en) 2014-12-18
SG178781A1 (en) 2012-03-29
NL301207I2 (nl) 2023-02-02
MX2010002590A (es) 2010-03-26
TW201412774A (zh) 2014-04-01
IL250900A0 (en) 2017-04-30
US8163284B2 (en) 2012-04-24
FR22C1059I1 (fr) 2023-02-03
LUC00289I2 (enExample) 2025-05-12
SG10201506251YA (en) 2015-11-27
MY150242A (en) 2013-12-31
CY1117702T1 (el) 2017-05-17
EP2703414A1 (en) 2014-03-05
US10287348B2 (en) 2019-05-14
EP2205635A1 (en) 2010-07-14
LTPA2022016I1 (enExample) 2023-01-10

Similar Documents

Publication Publication Date Title
CA2698382C (en) Antigen binding proteins capable of binding thymic stromal lymphopoietin
CA2662613C (en) Compositions and methods relating to glucagon receptor antibodies
TW200927167A (en) IL-18 receptor antigen binding proteins
KR20190013918A (ko) Etar 항체 및 이의 약학 조성물 및 용도
AU2014277673A1 (en) Antigen Binding Proteins Capable of Binding Thymic Stromal Lymphopoietin
HK40012723A (en) Antigen binding proteins capable of binding thymic stromal lymphopoietin
HK1195568A (en) Antigen binding proteins capable of binding thymic stromal lymphopoietin
HK1145843B (en) Antigen binding proteins capable of binding thymic stromal lymphopoietin